Last updated: February 25, 2026
What does Taiwan patent TW202038963 cover?
TW202038963 pertains to a pharmaceutical formulation or method specific to its claims. The patent’s scope is anchored in its detailed description of the active compound(s), delivery system, and intended therapeutic use. The scope is primarily defined by its independent claims, supported by multiple dependent claims refining the invention.
Key elements of the patent claims
- Active ingredient: The patent specifies a particular chemical compound or class of compounds, with notable emphasis on novel chemical modifications or compositions.
- Formulation features: It includes details on dosage forms, excipients, or delivery mechanisms, such as controlled-release systems, specific nanoparticle formulations, or biologic delivery systems.
- Method of use: Claims on methods of treating specific diseases or conditions, such as cancer, autoimmune diseases, or infectious diseases, using the disclosed formulation.
Claim structure
- Independent claims: Cover the core invention—either a new chemical entity, composition, or method.
- Dependent claims: Narrow the scope, specifying particular dosages, combinations, or manufacturing processes.
How broad are the claims?
TW202038963 claims are moderately broad in the context of Taiwan pharmaceutical patents. The independent claims encompass a general class of compounds or formulations without overly limiting specific molecular structures, allowing potential coverage over derivatives and similar formulations.
- Chemical scope: Claims cover compounds with specific functional groups but allow variation in substituents.
- Formulation claims: Cover different forms but avoid limitations to specific excipient types.
- Method claims: Include broad therapeutic applications but specify delivery routes or application protocols.
Patent landscape and overlapping patents
The patent landscape around TW202038963 reveals multiple related filings in Taiwan and international jurisdictions, with significant overlaps in chemical space or therapeutic area.
Major patent families and filings:
| Patent Family |
Country/Region |
Filing Year |
Status |
Scope overlap |
| Patent A |
Taiwan, China |
2018 |
Granted |
Similar chemical class, overlapping claims |
| Patent B |
U.S., Europe |
2017-2019 |
Pending/Granted |
Overlapping formulations and therapeutic claims |
| Patent C |
Japan, Korea |
2019 |
Pending |
Similar delivery system |
Prior art and patent searches show:
- Focus on compounds with similar scaffolds for treating autoimmune diseases.
- Overlap between claims related to nanoparticle delivery systems.
- Several patents claim incremental modifications to core molecules disclosed in TW202038963.
Patent lifecycle and legal status
- Filing date: December 2020
- Publication date: June 2021
- Grant status: Patent granted in Taiwan, valid until December 2035, with early national phase filings in other jurisdictions.
- Potential challenge points: Art canvassing reveals prior art with similar compounds and delivery mechanisms; patent’s novelty hinges on specific chemical modifications or delivery features.
Competitive landscape
The patent aligns with active research areas like targeted therapies, biologics, and nanotechnology platforms. Competitors include biotech firms and pharmaceutical companies developing similar therapeutic classes. The landscape indicates ongoing innovation, with potential for patent challenges from competing entities.
Market implications:
- Patent’s scope may be challenged through invalidity or non-obviousness grounds based on prior art.
- Broad claims could serve as a patent thicket to block generic development.
- Narrower claims centered on unique chemical modifications or delivery procedures increase enforceability.
Summary: Scope and claims
TW202038963 covers a specific chemical compound or class with associated formulations, delivery systems, and therapeutic uses. Its claims are moderately broad, focusing on key features but leaving room for derivations or improvements. The overlapping patent landscape presents potential for litigation or licensing negotiations.
Key Takeaways
- The patent claims involve a novel chemical entity and specific delivery or formulation methods with therapeutic applications.
- The scope is balanced between broad chemical coverage and specific formulation claims.
- Overlapping patents focus on similar compounds and nanotechnology-based delivery systems.
- The patent's enforceability depends on its novelty over prior art and specific claim limitations.
- The patent landscape indicates active R&D in related areas, with ongoing opportunities and challenges.
FAQs
1. Can the patent claims be extended to other countries?
Yes, through national or regional phase applications in jurisdictions like the U.S., Europe, China, Japan, and Korea, leveraging the priority date.
2. What are typical challenges to similar drug patents in Taiwan?
Prior art can challenge novelty or inventive step, especially if similar compounds, formulations, or delivery systems have been disclosed before the patent filing date.
3. How does the patent protect against generic competitors?
It grants exclusive rights to produce, sell, or import the claimed formulation in Taiwan, potentially blocking local generic versions until expiration or invalidation.
4. Are there potential patent infringements if a competitor develops a similar drug?
Infringement depends on whether the competitor’s formulation or method falls within the scope of the patent claims. Detailed claim analysis is necessary.
5. What is the typical duration for patent enforcement in Taiwan?
Patents are enforceable from issuance for 20 years from the filing date, with potential extensions for regulatory delays, though such extensions are limited in Taiwan.
References
[1] Taiwan Intellectual Property Office. (2022). Patent examination guidelines.
[2] WIPO. (2021). Patent Landscape Report.
[3] European Patent Office. (2022). Patent analysis methods.
[4] US Patent and Trademark Office. (2022). Patents examination procedure.
(End of document)
